Altimmune, Inc. — Director's Dealing 2022

Jan 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2021-12-31

Reporting Person: Eisenstadt Richard I (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-31	Stock Options (option to buy)	$9.16	A	150000	Acquired	2031-12-31	Common Stock, par value $0.0001 (150000)	Direct
2021-12-31	Restricted Stock Units	$	A	50000	Acquired		Common Stock, par value $0.0001 (50000)	Direct

Footnotes

F1: The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on December 31, 2022, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

F3: The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on December 31, 2022, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.